^
    Back
    Association details:
    Biomarker:APC mutation
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncol Res
    Title:

    Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer

    Published date:
    09/25/2023
    Excerpt:
    APC mutation status was a significantly enriched factor in responders to bevacizumab treatment.
    DOI:
    10.32604/or.2023.030374